Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.45 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084008 | 0.79 | L3MBTL1 (0.51) | ALDH1A1 | |
| SCHEMBL19075730 | 0.78 | NPC1 (0.48) | ALDH1A1 | |
| SCHEMBL701391 | 0.78 | TAS1R3 (0.76) | TAS1R3TAS1R1BCL2L1GRNSORT1 | |
| SCHEMBL701392 | 0.78 | TAS1R3 (0.76) | TAS1R3TAS1R1BCL2L1GRNSORT1 | |
| SCHEMBL7424626 | 0.76 | PDE4A (0.66) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL8323597 | 0.76 | PDE4A (0.66) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL19083819 | 0.75 | L3MBTL1 (0.68) | ALDH1A1POLB | |
| SCHEMBL19083995 | 0.74 | TAS1R3 (0.62) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL13091305 | 0.73 | TAS1R3 (0.62) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL878985 | 0.72 | TAS1R3 (0.61) | TAS1R3TAS1R1GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | TAS1R3 2742/4885TAS1R1 2598/4885BCL2L1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.